anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a medicament and to the use of a photo-reactive and/or -catalysable active ingredient for the production of this medicament for the treatment of superficial fungal, bacterial and/or viral disorders. The invention further relates to a treatment instrument for the treatment of superficial microbial, bacterial and viral disorders using this medicament. Instead of the prior-art method of using long exposure times, high active-ingredient concentrations or high levels of radiation to achieve efficient elimination of microbes, the present invention proposes in particular treating superficial microbial, bacterial and/or viral disorders with a photo-reactive active ingredient which comprises a photo-catalyst. This method can bring about the photo-reactive activity of the active ingredient even using relatively low levels of irradiation with light, and the reaction time can therefore be short, as also therefore can the exposure time. This promotes treatment which has no aggressive action on the tissue and is nevertheless highly effective. This is a particularly efficient method of controlling superficial fungal, bacterial or viral infection of the skin, examples being herpes, athlete's foot, acne, psoriasis, mycosis of the nails or inflammation of the nail bed, and corresponding disorders in the oral cavity region, particularly microbial infection of gingival pockets and of tooth root canals. In order to permit ideal activation of the medicament in each case under various conditions of use without any need to maintain stock of a wide variety of treatment instruments, the invention proposes a treatment instrument of which an operating head, having an illumination device for the irradiation of the medicament, has an implement-change-over device by means of which it is possible to fasten, to the operating head, implements whose shape is matched to various surfaces to be treated. An advantage here is integration of the illumination device into the operating head so that the implement can be changed over without any need for concomitant changeover of the illumination device which remains on the operating head.
Insect repellent or incense in coils or other configurations is made substantially of a combustible hydrocarbon material especially amorphous carbon. The amorphous carbon may be charcoal or activated carbon. Particularly and advantageously, insect repellent or incense coils are made by grinding and mixing charcoal or activated carbon, a binder agent, and water into a paste. The paste is extruded to form a flat sheet. A coil imprint is stamped in turn on said flat sheet. The imprints are either dipped in or sprayed with chemicals-in-alcohol solution. The chemicals include an active ingredient and perfume (in the case of making insect repellent) perfume (in the case of making incense). The treated imprints are air-dried and then packed. <IMAGE>
Sevelamer carbonate powder is available in 0.8 or 2.4 g packets. For dose increments of 0.4 g, use one half of a 0.8 g packet. Place the sevelamer carbonate powder in a cup and suspend in the amount of water described in Table 4.

Instruct patients to stir the mixture vigorously (it does not dissolve), resuspend, if necessary, right before administration, and drink the entire preparation within 30 minutes.

As an alternative to water, the entire contents of the packet may be pre-mixed with a small amount of food or beverage and consumed immediately (within 30 minutes) as part of the meal. Do not heat sevelamer carbonate powder (e.g., microwave) or add to heated foods or liquids.
As the monotherapy of available analgesics is usually accompanied by serious side effects or limited efficacy in the management of chronic pain, multimodal analgesia is widely used to achieve improved benefit-to-risk ratios in clinic. Drug-drug salts are extensively researched to optimize the physicochemical properties of active pharmaceutical ingredients (APIs) and achieve clinical benefits compared with individual APIs or their combination. New drug-drug salt crystals metformin-ibuprofen (MET-IBU) and metformin-naproxen (MET-NAP) were prepared from metformin (MET) and two poorly water-soluble anti-inflammatory drugs (IBU and NAP) by the solvent evaporation method. The structures of these crystals were confirmed by single crystal and powder X-ray diffraction, Hirshfeld surface, Fourier transform infrared spectroscopy and thermal analysis. Both MET-IBU and MET-NAP showed significantly improved solubility and intrinsic dissolution rate than the pure IBU or NAP. The stability test indicated that MET-IBU and MET-NAP have excellent physical stability under stressing test (10 days) and accelerated conditions (3 months). Moreover, isobolographic analysis suggested that MET-IBU and MET-NAP exerted potent and synergistic antinociceptive effects in λ-Carrageenan-induced inflammatory pain in mice, and both of them had an advantage in rapid pain relief. These results demonstrated the potential of MET-IBU and MET-NAP to achieve synergistic antinociceptive effects by developing drug-drug salt crystals.
Subjects will have a comprehensive eye examination once they express an interest in the study. This includes a slit lamp examination of the front of the eye and a dilated fundoscopic examination of the back of the eye. If there is any pathology noted that would exclude the subject from the study, then we will inform the patient and make an appropriate referral. if the subject is deemed appropriate for the study after a comprehensive examination included computerized videokeratography, then they can be enrolled. Subjects will undergo bilateral simultaneous eye surgery. Which eye is treated with the WFG-LASIK and which eye is treated with SMILE will be randomized so there is a 50% chance for either eye to receive one treatment. Subjects will be seen on the day of surgery, post op day one, one week, one month, three months, six months and one year. Subjects will receive topical antibiotics in each eye for one week following the procedure. Subjects will receive topical steroid ophthalmic drops for one week after treatment. Subjects will also receive topical antibiotic ophthalmic drops for four days after treatment. All of this is within the usual and customary standard of care for the treatment of subjects undergoing LASIK and SMILE surgery.
There will be 3 dose groups, 1 to 3 with escalating antigen dose with PIKA adjuvant in sequential cohorts. Arm B1 will enroll subjects who received Inactivated vaccines and will comprise of 15 subjects per dose. In arm B1, fifteen eligible subjects in each dose group will receive the study vaccine on Study Days 0 via intramuscular injection in alternative deltoid muscles.
Semi-structured sociodemographic data form, Sabotage in Romantic Relations Questionnaire (RISA), Self-Sabotage Questionnaire, was given to the participants after the interview to be conducted by volunteers aged 18 and over and having a romantic relationship and a psychiatrist working at the Sultan Abdulhamid Han Training and Research Hospital Mental Health and Diseases Service. The Perceived Romantic Relationship Quality Scale (SRS), the Perceived Romantic Relationship Quality Scale (ARIÖ), and the Attitudes Related to Love Scale (AİTÖ) will be given and they will be asked to fill in these forms. Participants will be divided into three study groups. The first study group will consist of at least 30 people for the Linguistic Equivalence Review of the scale. The second study group will consist of at least 30 people for the Confirmatory Factor Analysis, Equivalent Scale Validity and Cronbach Alpha Internal Consistency Reliability Coefficient Examination of the scale. The third study group will consist of at least 30 people for Test/Retest Reliability Analysis, and the same tests will be re-administered to the participants three weeks later. The selection of the sample will be made by simple random sampling method. The criteria given by Tabachnick and Fidell (2007) for factor analysis will be taken into account in determining the number of the research sample. According to these researchers, 300 people are evaluated as "good", 500 people as "very good" and 1000 people as "excellent" for factor analysis.

Back translation method will be used in the translation study of the Sabotage in Romantic Relations Questionnaire (RISA) (Brislin, 1970). First of all, the original form of the scale will be translated into Turkish by at least three experts with a doctorate degree in psychiatry and/or clinical psychology and at least three English language experts, independently of each other with a good level of English. The created form will be translated back into English by the researchers, a psychiatrist or clinical psychologist and two English Language experts. Both English and Turkish translations of the scale will be brought together by creating a "Language Validity Examination Form" (Seçer, 2015, p. 70) by the researchers. The Language Validity Examination Form will be compared by experts and evaluated in terms of translation suitability, and the final form of the scale will be decided by choosing the most appropriate items that reflect the theoretical structure better and are more linguistically understandable by majority vote.

Analysis of study data will be done using SPSS for Windows 22.0 and AMOS 24.0 package programs. In statistical interpretations, p\<.05 values will be considered significant at the 95% confidence interval.
An automatic screening apparatus that screens all pap smear slides called normal by cytotechnologist. These normal pap smears will contain the mistakes, false negatives, which must be recovered as a measure of the cytotechnologist's performance. Additionally, these mistakes must be discovered to improve the quality of the laboratory services. The automated screening machine after rescreening the normals, rank orders of the pap smears with those "normals" most likely to be missed ranked at the top. Another human screener re-examines those pap smears with high ranking to determine if the first human screener misclassified the pap smear. Mistakes are recovered and the performance of the first screener is assessed. Proficiency testing is accomplished with 100% quality control.
Weekly yoga classes will each be taught by two yoga instructors. Classes will be 75 minutes long. Mats and props will be provided. Yoga participants will be encouraged to practice for 30 minutes on days when they do not have class. They will be provided free of charge with a participant handbook, mat, block, and strap to aid home practice. Yoga home practice videos will be placed online for home practice and the website will track time spent using the videos for home practice. DVDs will be provided for those that do not have consistent access to the internet at home.
Myocardial infarction (MI) leads to substantial cellular necrosis as a consequence of reduced blood flow and oxygen deprivation. Stimulating cardiomyocyte proliferation and angiogenesis can promote functional recovery after cardiac events. In this study, we explored a novel therapeutic strategy for MI by synthesizing a biomimetic nanovesicle (NV). This biomimetic NVs are composed of exosomes sourced from umbilical cord mesenchymal stem cells, which have been loaded with placental growth factors (PLGF) and surface-engineered with a cardiac-targeting peptide (CHP) through covalent bonding, termed Exo-P-C NVs. With the help of the myocardial targeting effect of homing peptides, NVs can be enriched in the MI site, thus improve cardiac regeneration, reduce fibrosis, stimulate cardiomyocyte proliferation, and promote angiogenesis, ultimately resulted in improved cardiac functional recovery. It was demonstrated that Exo-P-C NVs have the potential to offer novel therapeutic strategies for the improvement of cardiac function and management of myocardial infarction.
FIELD: medicine, ophthalmology. SUBSTANCE: invention proposes to perform an antiviral and/or antibacterial therapy and to use nitrogen-hydrosulfate-sodium waters from a borehole 21, passport 54-113-9, Khabarovsky region, Ulchsky district, Annenskie waters as a regeneration agent, 5 times per 24 h between instillations of antibiotics and/or antiviral agents. Water temperature is 22-24 C on 3-5 days of the treatment onset. Invention can be used for treatment of cornea inflammation. EFFECT: enhanced effectiveness of treatment. 1 tbl, 3 ex
The adaptive transfer of T cells redirected to cancer cells via chimeric Ag receptors (CARs) has produced clinical benefits for the treatment of hematologic diseases. To extend this approach to solid cancer, we screened CARs targeting surface Ags on human lung cancer cells using (to our knowledge) novel expression cloning based on the Ag receptor-induced transcriptional activation of IL-2. Isolated CARs were directed against fragile X mental retardation 1 neighbor (FMR1NB), a cancer-testis Ag that is expressed by malignant cells and adult testicular germ cells. Anti-FMR1NB CAR human T cells demonstrated target-specific cytotoxicity and successfully controlled tumor growth in mouse xenograft models of lung cancer. Furthermore, to protect CAR T cells from immune-inhibitory molecules, which are present in the tumor microenvironment, we introduced anti-FMR1NB CARs into 2-deoxy-glucose (2DG)-treated human T cells. These cells exhibited reduced binding affinity to immune-inhibitory molecules, and the suppressive effects of these molecules were resisted through blockade of the N-glycosylation of their receptors. Anti-FMR1NB CARs in 2DG-treated human T cells augmented target-specific cytotoxicity in vitro and in vivo. Thus, our findings demonstrated the feasibility of eradicating lung cancer cells using 2DG-treated human T cells, which are able to direct tumor-specific FMR1NB via CARs and survive in the suppressive tumor microenvironment.
The invention discloses a water-soluble drug sustained-release microsphere and a preparation method and applications thereof. The microsphere comprises an inner core area and an outer core dispersing area; the inner core area is formed by using an isolating oil phase to seal the water-soluble drug; the outer core dispersing area is a medical macromolecular accessory. The invention discloses the preparation method for the water-soluble drug sustained-release microsphere; the medical macromolecular accessory is dissolved into an organic solvent to form a dispersing medium; the powder of the water-soluble drug is dispersed into an isolating layer oil phase to form suspension liquid and slowly release into the dispersing medium; then the suspension liquid is prepared into first milk; then the first milk is prepared into emulsion. The organic solvent is volatilized to form the microsphere; the suspension liquid dispersed with the microsphere is centrifugated, filtered, washed, dried and collected, thus obtaining the microsphere. The invention also discloses an emulsion-solvent vaporizing method to prepare the water-soluble drug sustained-release microsphere and the applications of the preparation method in different drug preparations. The microsphere preparation technique is stable, and practical; the shape of the microsphere is round; the surface is smooth, the fluidity is good and the granularity distribution is uniform.
This review paper delves into the intricate relationship between the genital microbiome and fertility outcomes in livestock, with a specific focus on cattle. Drawing upon insights derived from culture-independent metagenomics studies, the paper meticulously examines the composition and dynamics of the genital microbiome. Through advanced techniques such as high-throughput sequencing, the review illuminates the temporal shifts in microbial communities and their profound implications for reproductive health. The analysis underscores the association between dysbiosis-an imbalance in microbial communities-and the development of reproductive diseases, shedding light on the pivotal role of microbial gatekeepers in livestock fertility. Furthermore, the paper emphasizes the need for continued exploration of uncharted dimensions of the female reproductive microbiome to unlock new insights into its impact on fertility. By elucidating the complex interplay between microbial communities and reproductive health, this review underscores the importance of innovative strategies aimed at enhancing fertility and mitigating reproductive diseases in livestock populations.
The selection of the starting dose for pediatric participants is based on the PK extrapolation from adults, taking into account the children body weight category, in order to lead to an exposure similar to that in adult PAH participants at a starting dose of 200 micrograms (mcg). As in adults, selexipag will be up-titrated to the individual maximum tolerated dose (iMTD) during the first 12 weeks. Approximately 60 participants will be enrolled in 3 different age cohorts to obtain at least 45 participants with evaluable PK profiles: Cohort 1: \>= 12 to \< 18 years of age, Cohort 2: \>= 6 to \< 12 years of age, Cohort 3: \>= 2 to \< 6 years of age. In each age cohort the starting dose will depend on the body weight. Enrollment will start with both Cohort 1 and Cohort 2. After completion of PK assessments in at least 15 participants from Cohort 1 at Week 12, a first interim analysis will be conducted to establish the dose-exposure relationship using a population PK model. The PK data from any participants in Cohort 2 who have completed their PK assessments at this time will be included in this first interim analysis. Results of this model-based analysis will be used to confirm or adjust the selexipag doses initially selected. Enrollment of Cohort 3 (children \>= 2 to \< 6 years of age) will start once the appropriate doses have been confirmed in a second interim analysis of PK data from Cohorts 1 and 2, and if there is no safety concern based on review by an Independent Data Monitoring Committee (IDMC).
The placebo group received orally two lactose tablets per day for 30 days. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption.
The invention concerns the use of substances which activate lipolysis having the specific property to stimulate protein G activity. Said cell membrane proteins have a switching role in transmitting the signal from outside into the cell. In adipocytes they activate lipolysis. Their stimulation by substances such as GDP (guanosine diphosphate) or GTPηS (guanosine 5'-[η-thio] triphosphate) or Gpp[NH]p (5'guanylylimidodiphosphate) and by plant extracts, obtained from plants selected inter alia among the genus Armeniacea, Atractylodis, Sinomenum, Bupleurum, Pharbitidis and Coleus, can be used in cosmetics. The use of these substances and plant extracts is novel. The extracts are obtained preferably by hydroglycolitic or alcoholic maceration. They are useful for preparing cosmetic and dermopharmaceutical compositions for their slimming and toning properties.
Patient will receive Ketamine at a dose of 30 mg every eight hours. It will be mixed with apple juice prior to administration and taken orally. Patients will receive Ketamine for three days or nine doses total.
PURPOSE: Antibiotic coprisin is provided to be able to be usefully used as antibiotics and antiphlogistics safe to the human body as the antibiotic coprisin isolated from Copris tripartitus larva has little cytotoxicity. CONSTITUTION: A pharmaceutical composition comprises the peptide of Sequence number 1 as an active ingredient. The composition has no cytotoxicity to the red blood cell of human or the mammalia normal cell. An antibacterial composition to microorganism includes the peptide of Sequence number 1 as an active ingredient. The microorganism is Gram-positive bacteria, Gram-negative bacteria or a strain with antibiotic tolerance. The Gram-positive bacteria is B. subtilis, S. aureus, or S. epidermidis, and the Gram-negative bacteria is E. coli, P. aeruginosa or S. typhimurium. The strain with antibiotic tolerance is vancomycin resistant staphylococcus aureus (MRSA), multi-drug resistant S. typhimurium (MDRST), or antibiotics resistant E. coli (MDREC).
The need for the delivery of insulin by injection can be reduced or eliminated by a method whereby an aerosolized insulin formulation is delivered to a patient's lungs and the rate at which the insulin is absorbed into the blood is increased by the use of an inhale-exhale breathing maneuver. Particles of insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The rate of absorption is enhanced by instructing the patient to inhale maximally and thereafter exhale maximally. This maneuver causes a spike in the rate at which insulin enters the circulatory system thereby increasing the rate at which glucose is removed from the circulatory system. The insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation. The device includes a sensor which is preferably electronic which measures inspiratory flow and volume which measurement can be used to control the point of drug release. The sensor can also assist the patient in the inhale-exhale maneuver.
BACKGROUND: Alzheimer's disease (AD) and amyotrophic lateral sclerosis/frontotemporal dementia (ALS/FTD) are debilitating neurodegenerative diseases for which there are currently no cures. Familial cases with known genetic causes make up less than 10% of these diseases, and little is known about the underlying mechanisms that contribute to sporadic disease. Accordingly, it is important to expand investigations into possible pathways that may contribute to disease pathophysiology. Glycerophosphodiester phosphodiesterase 2 (GDE2 or GDPD5) is a membrane-bound enzyme that acts at the cell surface to cleave the glycosylphosphatidylinositol (GPI)-anchor that tethers distinct proteins to the membrane. GDE2 abnormally accumulates in intracellular compartments in the brain of patients with AD, ALS, and ALS/FTD, indicative of GDE2 dysfunction. Mice lacking GDE2 (Gde2KO) show neurodegenerative changes such as neuronal loss, reduced synaptic proteins and synapse loss, and increased Aβ deposition, raising the possibility that GDE2 disruption in disease might contribute to disease pathophysiology. However, the effect of GDE2 loss on behavioral function and learning/memory has not been characterized.
RESULTS: Here, we show that GDE2 is expressed throughout the adult mouse brain in areas including the cortex, hippocampus, habenula, thalamus, and amygdala. Gde2KO and WT mice were tested in a set of behavioral tasks between 7 and 16 months of age. Compared to WT, Gde2KO mice display moderate hyperactivity that becomes more pronounced with age across a variety of behavioral tests assessing novelty-induced exploratory activity. Additionally, Gde2KO mice show reduced startle response, with females showing additional defects in prepulse inhibition. No changes in anxiety-associated behaviors were found, but Gde2KOs show reduced sociability. Notably, aged Gde2KO mice demonstrate impaired short/long-term spatial memory and cued fear memory/secondary contextual fear acquisition.
CONCLUSIONS: Taken together, these observations suggest that loss of GDE2 leads to behavioral deficits, some of which are seen in neurodegenerative disease models, implying that loss of GDE2 may be an important contributor to phenotypes associated with neurodegeneration.